Coty Faces Securities Fraud Lawsuit Amid Turnaround Struggles

What happened

A securities fraud class action lawsuit has been filed against Coty Inc. by Glancy Prongay Wolke & Rotter LLP on behalf of investors who purchased stock between November 5, 2025, and February 4, 2026. This period aligns with Coty's reported financial deterioration, including a 4% revenue decline in FY25 and a net loss driven by $212.8 million in trademark impairments and derivative losses. The lawsuit alleges potential fraud, adding legal overhang to an already high-risk equity characterized by elevated leverage (net debt/EBITDA 4.2x) and volatile earnings. Investors now confront both operational and legal uncertainties as Coty attempts to execute its fragile turnaround, including cost reductions and a strategic review of its loss-making Consumer Beauty segment. Management must navigate these challenges while addressing structural issues, with the stock down ~56% over the past year reflecting deep skepticism.

Implication

The lawsuit introduces significant legal risk that could drain financial resources and distract management from critical operational improvements, such as cost savings and Consumer Beauty restructuring. It may further erode investor confidence, pressuring the stock price and making it harder for Coty to access capital needed for deleveraging. Long-term, if allegations are substantiated, it could lead to financial penalties and reputational damage, undermining brand equity in its core fragrance business. However, if Coty successfully defends itself and demonstrates progress on strategic initiatives, the impact might be contained, though execution remains a high hurdle. Nonetheless, the added uncertainty reinforces the need for caution, aligning with the DeepValue report's 'WAIT' stance until clearer signs of stabilization and deleveraging emerge.

Thesis delta

The lawsuit does not fundamentally alter the core investment thesis but exacerbates existing risks by introducing potential legal liabilities and management distraction. It could delay or derail the already fragile turnaround, particularly if it leads to increased costs or loss of investor trust. Therefore, the stance remains 'WAIT,' but with heightened caution due to increased uncertainty around execution and balance sheet health.